Security
Ocugen, Inc. Common Stock · OCGN
OCGNNASDAQCommon stockCurrentCIK 1372299Updated Nov 16, 2026
OCGN price & chart
Loading TradingView…
NASDAQ:OCGN on TradingView ↗About the company
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company's breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen's modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow the Company on LinkedIn and X.
In the news
Ocugen to Participate in Upcoming Scientific Conferences ↗
Recent filings
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
DEFA14A filing
DEFA14A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure · Other Events
Items 1.01, 7.01, 8.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Submission of Matters to a Vote of Security Holders
Items 5.07
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 57,596,000Source | 61,936,000Source | 124,206,000Source | 53,594,000Source | 40,542,000Source | 56,905,000Source | 64,460,000Source | 51,794,000Source | 43,516,000Source | 82,442,000Source | 96,299,000Source | 108,632,000Source |
| Property, Plant and Equipment, NetUSD | 14,946,000Source | 17,130,000Source | 13,347,000Source | 15,445,000Source | 17,474,000Source | 13,830,000Source | 15,989,000Source | 17,654,000Source | 14,392,000Source | 16,554,000Source | 7,952,000Source | 6,053,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | 100,051,000Source | 27,013,000Source | 15,697,000Source | 31,900,000Source | 37,800,000Source | 26,375,000Source | — | — | 68,259,000Source | 77,563,000Source |
| Assets, CurrentUSD | 37,639,000Source | 40,673,000Source | 106,721,000Source | 32,883,000Source | 18,617,000Source | 38,551,000Source | 43,964,000Source | 29,998,000Source | 24,340,000Source | 61,682,000Source | 84,401,000Source | 98,492,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,074,000Source | 1,977,000Source | 6,670,000Source | 5,870,000Source | 2,920,000Source | 6,696,000Source | 6,164,000Source | 3,623,000Source | 5,769,000Source | 3,168,000Source | 7,680,000Source | 7,558,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | 4,092,000Source | 3,613,000Source | — | 3,910,000Source |
| Other Assets, NoncurrentUSD | 4,697,000Source | 3,828,000Source | 3,818,000Source | 4,954,000Source | 4,149,000Source | 4,206,000Source | 4,198,000Source | 4,142,000Source | 4,468,000Source | 3,899,000Source | 3,946,000Source | 4,087,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 54,063,000Source | 21,306,000Source | 140,762,000Source | 50,542,000Source | 23,615,000Source | 51,100,000Source | 48,546,000Source | 21,533,000Source | 55,682,000Source | 52,810,000Source | 31,398,000Source | 24,580,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | — | 0Source | 0Source | — | — | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 3,125,000Source | 2,904,000Source | 3,390,000Source | 2,924,000Source | 2,576,000Source | 3,384,000Source | 2,922,000Source | 2,575,000Source | 3,125,000Source | 2,915,000Source | 2,265,000Source | 2,217,000Source |
| Additional Paid in CapitalUSD | 390,759,000Source | 364,092,000Source | 432,010,000Source | 370,474,000Source | 327,742,000Source | 429,549,000Source | 368,571,000Source | 325,799,000Source | 392,763,000Source | 366,938,000Source | 303,073,000Source | 294,874,000Source |
| Retained Earnings (Accumulated Deficit)USD | -390,361,000Source | -326,341,000Source | -452,121,000Source | -370,310,000Source | -313,371,000Source | -427,244,000Source | -355,571,000Source | -298,091,000Source | -408,067,000Source | -340,221,000Source | -240,415,000Source | -213,018,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 58,000Source | 23,000Source | 213,000Source | 12,000Source | 28,000Source | 164,000Source | 40,000Source | 25,000Source | 61,000Source | 48,000Source | 25,000Source | 26,000Source |
| Stockholders' Equity Attributable to ParentUSD | 3,533,000Source | 40,630,000Source | -16,556,000Source | 3,052,000Source | 16,927,000Source | 5,805,000Source | 15,914,000Source | 30,261,000Source | -12,166,000Source | 29,632,000Source | 64,901,000Source | 84,052,000Source |
| Liabilities and EquityUSD | 57,596,000Source | 61,936,000Source | 124,206,000Source | 53,594,000Source | 40,542,000Source | 56,905,000Source | 64,460,000Source | 51,794,000Source | 43,516,000Source | 82,442,000Source | 96,299,000Source | 108,632,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 20,361,000Source | 15,762,000Source | 133,080,000Source | 17,989,000Source | 17,972,000Source | 20,708,000Source | 16,886,000Source | 16,050,000Source | 23,043,000Source | 21,588,000Source | 26,582,000Source | 18,460,000Source |
| Operating Lease, Liability, CurrentUSD | 855,000Source | 477,000Source | 839,000Source | 853,000Source | 461,000Source | 850,000Source | 736,000Source | 589,000Source | 858,000Source | 519,000Source | 512,000Source | 498,000Source |
| Accounts Payable, CurrentUSD | 4,574,000Source | 1,494,000Source | 5,140,000Source | 4,237,000Source | 3,391,000Source | 3,241,000Source | 3,224,000Source | 1,731,000Source | 6,202,000Source | 4,243,000Source | 8,092,000Source | 8,062,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,709,000Source | 3,419,000Source | 3,039,000Source | 3,945,000Source | 3,546,000Source | 3,252,000Source | 3,418,000Source | 3,414,000Source | 3,494,000Source | 3,313,000Source | 3,449,000Source | 3,587,000Source |
| Other Liabilities, NoncurrentUSD | 1,593,000Source | 554,000Source | 2,914,000Source | 583,000Source | 545,000Source | 2,951,000Source | 573,000Source | 536,000Source | 1,603,000Source | 564,000Source | 309,000Source | 244,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 9,900,000Source |
| Long-term Debt, Current MaturitiesUSD | 0Source | 1,316,000Source | 20,000Source | 0Source | 1,306,000Source | 5,005,000Source | 0Source | 1,296,000Source | 1,250,000Source | 1,326,000Source | 1,256,000Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 28,400,000Source | 1,571,000Source | 1,729,000Source | 28,025,000Source | 1,552,000Source | 24,189,000Source | 27,669,000Source | 1,533,000Source | 27,542,000Source | 27,345,000Source | 1,058,000Source | 2,289,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | -81,351,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 590,000Source | 595,000Source | 2,389,000Source | 1,968,000Source | 704,000Source | 480,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -21,794,000Source | -19,357,000Source | -56,964,000Source | -42,142,000Source | -62,054,000Source | -60,079,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -6,000Source | -102,000Source | -311,000Source | -3,385,000Source | 3,077,000Source | -16,967,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 6,000Source | 16,000Source | 185,000Source | 3,385,000Source | 10,476,000Source | 4,457,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 34,984,000Source | -1,245,000Source | 17,328,000Source | 64,858,000Source | 20,881,000Source | 59,475,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 13,286,000Source | -20,712,000Source | -39,934,000Source | 19,359,000Source | -38,101,000Source | -17,546,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 32,879,000Source | 39,001,000Source | 100,371,000Source | 27,325,000Source | 32,173,000Source | 38,109,000Source | 18,887,000Source | 58,821,000Source | 39,462,000Source | 77,563,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 102,000Source | -8,000Source | 13,000Source | 28,000Source | -5,000Source | 25,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,976,000Source | 1,892,000Source | 1,833,000Source | 1,845,000Source | 3,398,000Source | 1,885,000Source | 7,707,000Source | 7,427,000Source | 9,217,000Source | 10,541,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 400,000Source | — | — | — | 377,000Source | 314,000Source | 1,362,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | 600,000Source | 600,000Source | 600,000Source | 600,000Source | 2,400,000Source | 1,900,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | -363,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | -2,383,000Source | 0Source | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 8,228,000Source | 6,280,000Source | 7,242,000Source | 6,766,000Source | 8,117,000Source | 6,453,000Source | 27,579,000Source | 26,686,000Source | 31,994,000Source | 35,111,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 1,314,000Source | 29,000Source | 4,476,000Source | 1,285,000Source | 1,320,000Source | 1,257,000Source | 5,188,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 207,000Source | 310,000Source | 395,000Source | 227,000Source | 132,000Source | 343,000Source | 922,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,051,000Source | -12,970,000Source | -24,877,000Source | -14,739,000Source | -19,177,000Source | -15,350,000Source | -67,846,000Source | -54,054,000Source | -63,078,000Source | -81,351,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -24,877,000Source | -14,739,000Source | -19,177,000Source | -15,350,000Source | — | — | -63,078,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -2,426,000Source | 282,000Source | -8,433,000Source | -944,000Source | -1,338,000Source | -849,000Source | -4,930,000Source | 703,000Source | 2,453,000Source | 3,517,000Source |
| Operating ExpensesUSD | — | — | 19,377,000Source | 14,388,000Source | 17,932,000Source | 15,168,000Source | 19,372,000Source | 15,982,000Source | 67,329,000Source | 58,812,000Source | 71,567,000Source | 84,868,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,319,000Source | 1,000Source | -78,000Source | 114,000Source | -150,000Source | 65,000Source | -664,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 22,500,000Source | 0Source | 19,854,000Source | 38,556,000Source | 20,804,000Source | 59,567,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 500,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | 0Source | 17,500,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 100,000Source | 200,000Source | 100,000Source | 1,300,000Source |
| Financing Receivable, Credit Loss, Expense (Reversal)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 1,752,000Source | 1,136,000Source | 1,488,000Source | 1,373,000Source | 1,533,000Source | 1,481,000Source | 4,413,000Source | 4,055,000Source | 6,036,000Source | — |
| Operating Income (Loss)USD | — | — | -17,625,000Source | -13,252,000Source | -16,444,000Source | -13,795,000Source | -17,839,000Source | -14,501,000Source | -62,916,000Source | -54,757,000Source | -65,531,000Source | -84,868,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -1,319,000Source | 1,000Source | -78,000Source | 114,000Source | -150,000Source | 65,000Source | -664,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -67,846,000Source | -54,054,000Source | -63,078,000Source | -81,351,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -20,051,000Source | -12,970,000Source | -24,877,000Source | -14,739,000Source | -19,177,000Source | -15,350,000Source | -67,846,000Source | -54,054,000Source | -63,078,000Source | -81,351,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -0.07Source | -0.05Source | -0.06Source | -0.05Source | — | — | -0.26Source | -0.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -0.07Source | -0.05Source | -0.06Source | -0.05Source | — | — | -0.26Source | -0.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 338,679,856Source | 292,067,192Source | 327,543,855Source | 291,996,562Source | — | — | 244,327,057Source | 214,600,051Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 338,679,856Source | 292,067,192Source | 327,543,855Source | 291,996,562Source | — | — | 244,327,057Source | 214,600,051Source |
| Interest Expense (non-operating)USD | — | — | 1,314,000Source | 29,000Source | 4,476,000Source | 1,285,000Source | 1,320,000Source | 1,257,000Source | 5,188,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 8,228,000Source | 6,280,000Source | 7,242,000Source | 6,766,000Source | 8,117,000Source | 6,453,000Source | 27,579,000Source | 26,686,000Source | 31,994,000Source | 35,111,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -66,031,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | 300,000Source | — | -1,058,000Source | — | -914,000Source | — | 1,300,000Source | 2,500,000Source | 1,400,000Source |
| Investment Income, InterestUSD | — | — | 207,000Source | 310,000Source | 395,000Source | 227,000Source | 132,000Source | 343,000Source | 922,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -24,877,000Source | -14,739,000Source | -19,177,000Source | -15,350,000Source | — | — | -63,078,000Source | — |
| Nonoperating Income (Expense)USD | — | — | -2,426,000Source | 282,000Source | -8,433,000Source | -944,000Source | -1,338,000Source | -849,000Source | -4,930,000Source | 703,000Source | 2,453,000Source | 3,517,000Source |
| Operating ExpensesUSD | — | — | 19,377,000Source | 14,388,000Source | 17,932,000Source | 15,168,000Source | 19,372,000Source | 15,982,000Source | 67,329,000Source | 58,812,000Source | 71,567,000Source | 84,868,000Source |
| Research and Development ExpenseUSD | — | — | 11,149,000Source | 8,108,000Source | 10,690,000Source | 8,402,000Source | 11,255,000Source | 9,529,000Source | 39,750,000Source | 32,126,000Source | — | — |
| Interest Expense, Debt | — | — | —Source | — | — | —Source | —Source | —Source | — | — | — | — |
Filing attachments
tm2629434d1_ex99-1.htm · 8-K · 2026-11-10
Exhibit 99.1 Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) markets Expands access to a potential one-time treatment gene therapy for RP across a region with an estimated 725 mi…
Read attachment ↗tm2628896d1_ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 Ocugen Provides Business Update with Third Quarter 2026 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Received Provisional Approval and Priority Designation for OCU400 in The Bahamas o Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) to coordinate and manage patient care o Progressing site readiness in preparation to accept patients o Advancing toward full approval and potential patient enr…
Read attachment ↗tm2628896d1_ex99-2.htm · 8-K · 2026-11-04
Exhibit 99.2 Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product can…
Read attachment ↗tm2627592d2_ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product can…
Read attachment ↗tm2627592d1_ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa October 14, 2026 Establishes strategic commercial reach across the Middle East and North Africa, advancing Ocugen’s goal of enabling global patient access to potentially transformational gene therapies Expands access to a potential one-time gene therapy for retinitis pigmentosa in a region with high disease prevalence and su…
Read attachment ↗tm2624985d1_ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 tm2624985d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies to Market and Working Even Harder to Provide Access to Patients Globally 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinica…
Read attachment ↗